Pablo Antonio Urena Torres, MD, PhD
Clinique du Landy
Private Practice, Service of Nephrology and Dialysis
23, rue du Landy
93400 Saint Ouen
+33 1
Dr Pablo Antonio Ureña Torres is nephrologist at the Clinique du Landy, Service de Néphrologie-Dialyse, in Saint Ouen, France, as well as Consultant at the Service des Explorations Fonctionnelles at the Necker-Enfant Malades Hospital, Paris, France. Dr. Ureña Torres gained his medical degree from the Madre y Maestra Catholic University, Santiago, Dominican Republic (1983), a Nephrology Specialty Certificate from the University of Paris V, France (1989), a Master of Molecular Biology from Harvard University and the Massachusetts General Hospital of Boston, USA (1992), and a Diploma in Bone Biology from the Faculté Lariboisière, University of Paris VII (1996). Dr Ureña Torres has been working for more than 20 years in the field of diagnosis, prevention, treatment and evolution of renal osteodystrophy or CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorders). In his research, Dr Ureña Torres has demonstrated: the capacity of certain dialysis membranes to bind and filter beta-2-microglobulin and ultimately prevent the occurrence of dialysis-related beta-2-microglobumin amyloidosis; that radiolabeled lipopolysaccharides or endotoxins could pass through most of hemodialysis membrane, which could be considered as one of the factors associated with the micro-inflammation observed during the hemodialysis treatment. This finding led in the 90s to the development of dialysate filters for dialysis machines (diasafe) that adsorb and remove lipopolysaccharides from the dialysate fluid; that in more than 65% of patients with severe secondary hyperparathyroidism, the removed parathyroid glands show a monoclonal cell growth pattern. He participated in the cloning and characterization of the parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor gene, and to its modification by the uremic situation. He has also largely participated at the development of calcimimetics as medical treatment for secondary hyperparathyroidism. During the last years, his research has been focused on the understanding the pathophysiology of new molecules such as klotho and fibroblast growth factor 23 (FGF23), as well as the old natural vitamin D, in case of chronic kidney disease. Dr. Ureña Torres is currently a core member of the CKD-MBD Working group of the EDTA. He is an active member of a number of societies, including the International Society of Nephrology, European Dialysis and Transplantation Association (ERA-EDTA), the American Association for the Advancement for Science (AAAS), the American Society for the Bone and Mineral Research (ASBMR), the American Association of Nephrology, and the French Société de Néphrologie. Dr Ureña Torres has authored or co-authored more than 190 scientific publications in peer-reviewed journal as well as several reviews and chapters in textbooks.